A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
المؤلفون المشاركون
Suyanto, Suyanto
Yeo, Daniel
Khan, Sarah
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-4، 4ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-03-03
دولة النشر
مصر
عدد الصفحات
4
التخصصات الرئيسية
الملخص EN
Immune checkpoint inhibitors such as Nivolumab work by preventing the inactivation of host T-cells by tumour cells, thereby allowing the T-cells to attack the tumour cells, which results in tumour tissue necrosis.
We describe a 78-year-old woman with metastatic lung adenocarcinoma treated with Nivolumab after disease progression following first-line chemotherapy.
Computed tomography (CT) after 3 cycles showed a smaller left lower lobe (LLL) primary and stable right lower lobe (RLL) metastatic lesion.
CT after 9 cycles showed a reduced RLL mass and an increase in LLL primary.
However, CT after 15 cycles showed that the RLL mass had further reduced in size but the LLL mass was significantly larger.
The biopsy of the LLL lesion showed necrotic areas and reactive inflammatory changes, without residual malignancy.
A repeat CT after further 4 cycles confirmed tumour regression in both the primary and the metastatic lesions.
There was a prior reported case of pseudoprogression in a non-small-cell lung cancer patient who had 7 cycles of Nivolumab, and it was diagnosed during a further line of chemotherapy.
Here, we report a patient with pseudoprogression during treatment with Nivolumab and at a much later time, after 15 cycles.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Suyanto, Suyanto& Yeo, Daniel& Khan, Sarah. 2019. A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1142153
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Suyanto, Suyanto…[et al.]. A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-4.
https://search.emarefa.net/detail/BIM-1142153
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Suyanto, Suyanto& Yeo, Daniel& Khan, Sarah. A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-4.
https://search.emarefa.net/detail/BIM-1142153
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1142153
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر